The forecast for peptic ulcer and gastro-oesophageal reflux diseases (GORD) medicine sales in Italy indicates a consistent decline from 2024 to 2028. In 2024, the sales are projected to constitute 2.5% of total sales, decreasing gradually to 1.6% by 2028. Compared to 2023, the year-on-year variation suggests a downward trend. This represents a compound annual growth rate (CAGR) that reflects an average annual decrease in sales percentage over the five-year period.
Future trends to watch include advancements in alternative therapies, changes in patient demographics, and regulatory shifts that could impact the demand for traditional medicines within this category.
